VEGFR2/CD309 anticorps (AA 20-764) (FITC)

N° du produit ABIN7175386

Cet anticorps anti-VEGFR2/CD309 est un anticorps Lapin Polyclonal détectant VEGFR2/CD309 dans . Adapté pour Humain.

Aperçu rapide pour VEGFR2/CD309 anticorps (AA 20-764) (FITC) (ABIN7175386)

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VEGFR2/CD309 est conjugé à/à la FITC

Application: Veuillez nous consulter SVP

Détail du produit anti-VEGFR2/CD309 anticorps (FITC)

Épitope: AA 20-764

Fonction: KDR Antibody, FITC conjugated

Purification: Protein G purified

Pureté: >95 %

Immunogène: Recombinant Human Vascular endothelial growth factor receptor 2 protein (20-764AA)

Isotype: IgG

Information d'application

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur VEGFR2/CD309

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Autre désignation: KDR

Sujet:

Background: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

Aliases: CD309 antibody, CD309 antigen antibody, EC 2.7.10.1 antibody, Fetal liver kinase 1 antibody, FLK-1 antibody, FLK1 antibody, FLK1, mouse, homolog of antibody, Kdr antibody, Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody, Kinase insert domain receptor antibody, KRD1 antibody, Ly73 antibody, Protein tyrosine kinase receptor FLK1 antibody, Protein-tyrosine kinase receptor flk-1 antibody, soluble VEGFR2 antibody, Tyrosine kinase growth factor receptor antibody, Vascular endothelial growth factor receptor 2 antibody, VEGFR 2 antibody, VEGFR antibody, VEGFR-2 antibody, VEGFR2 antibody, VGFR2_HUMAN antibody

UniProt: P35968

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling